A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19

[1]  Ali I. Al-Gareeb,et al.  Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality , 2022, International Immunopharmacology.

[2]  Ali I. Al-Gareeb,et al.  The possible role of ursolic acid in Covid-19: A real game changer , 2022, Clinical Nutrition ESPEN.

[3]  Y. Bertrand,et al.  Increased blood viscosity and red blood cell aggregation in patients with COVID‐19 , 2021, American journal of hematology.

[4]  S. Bayraktar,et al.  Pentoxifylline in the treatment of neonatal vasospasm and thromboembolism: An observational case series study , 2021, Journal of clinical pharmacy and therapeutics.

[5]  Ali I. Al-Gareeb,et al.  Niclosamide for Covid-19: bridging the gap , 2021, Molecular Biology Reports.

[6]  Ali I. Al-Gareeb,et al.  Acute kidney injury and COVID-19 , 2021, The Egyptian Journal of Internal Medicine.

[7]  Ali I. Al-Gareeb,et al.  Covid-19 and development of heart failure: mystery and truth , 2021, Naunyn-Schmiedeberg's Archives of Pharmacology.

[8]  Ali I. Al-Gareeb,et al.  Levamisole Therapy in COVID-19. , 2021, Viral immunology.

[9]  Ali I. Al-Gareeb,et al.  Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity , 2021, European Journal of Pharmacology.

[10]  Ali I. Al-Gareeb,et al.  Pleiotropic Effects of Tetracyclines in the Management of COVID-19: Emerging Perspectives , 2021, Frontiers in Pharmacology.

[11]  Jashanpreet Singh,et al.  Sunlight powered degradation of pentoxifylline Cs0.5Li0.5FeO2 as a green reusable photocatalyst: Mechanism, kinetics and toxicity studies. , 2021, Journal of hazardous materials.

[12]  M. Soto,et al.  Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19 , 2021, Computational and Structural Biotechnology Journal.

[13]  J. Guck,et al.  Physical phenotype of blood cells is altered in COVID-19 , 2021, bioRxiv.

[14]  C. Granger,et al.  Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. , 2021, JAMA.

[15]  Hanjin Cho,et al.  Pentoxifylline Restores T Cell Viability in Hyper-inflammatory Conditions , 2020 .

[16]  M. Revel,et al.  Pulmonary Embolism and Deep Vein Thrombosis in COVID-19: A Systematic Review and Meta-Analysis , 2020, Radiology.

[17]  D. Odde,et al.  mTOR inhibition in COVID‐19: A commentary and review of efficacy in RNA viruses , 2020, Journal of medical virology.

[18]  E. Avci,et al.  Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19 , 2020, The American Journal of Emergency Medicine.

[19]  Marco A. Loza-Mejía,et al.  Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study , 2020, International Immunopharmacology.

[20]  S. Perlman,et al.  COVID-19 Treatments and Pathogenesis Including Anosmia in K18-hACE2 mice , 2020, Nature.

[21]  A. M. Muñoz Martín,et al.  Thrombosis and Coagulopathy in COVID-19 , 2020, Current Problems in Cardiology.

[22]  Ali I. Al-Gareeb,et al.  COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors , 2020, Journal of microscopy and ultrastructure.

[23]  F. Hashemian,et al.  Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic , 2020, European Journal of Pharmacology.

[24]  N. de Las Heras,et al.  Implications of Oxidative Stress and Potential Role of Mitochondrial Dysfunction in COVID-19: Therapeutic Effects of Vitamin D , 2020, Antioxidants.

[25]  G. Lippi,et al.  Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[26]  M. Schaalan,et al.  Implications of miRNAs on TGF-β/TAK1/mTOR pathway in mediating the renoprotective effects of pentoxifylline against cisplatin-induced nephrotoxicity in rats. , 2020, Toxicology and applied pharmacology.

[27]  K. Appiah-Kubi,et al.  Platelet-Derived Growth Factors (PDGFs) are Key Players in the Stimulation of Airway Smooth Muscle Cells (ASMCs) Alteration in Asthma and Chronic Obstructive Pulmonary Disease (COPD) with Multifarious Inhibitors at an Early Stage of Development , 2020 .

[28]  T. Swartz,et al.  Targeting the NLRP3 Inflammasome in Severe COVID-19 , 2020, Frontiers in Immunology.

[29]  A. Sfera,et al.  Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis , 2020, Frontiers in immunology.

[30]  M. Abouelkhair.  Targeting adenosinergic pathway and adenosine A2A receptor signaling for the treatment of COVID-19: A hypothesis , 2020, Medical Hypotheses.

[31]  Suchi Goel,et al.  Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials , 2020, Journal of Biosciences.

[32]  B. Hendry,et al.  Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID‐19 patients , 2020, Pharmacology research & perspectives.

[33]  S. Assimakopoulos,et al.  Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal , 2020, Medical Hypotheses.

[34]  Vineet D. Menachery,et al.  The search for a COVID-19 animal model , 2020, Science.

[35]  L. Delgado-Roche,et al.  Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection , 2020, Archives of Medical Research.

[36]  P. Triggianese,et al.  The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19 , 2020, Journal of Autoimmunity.

[37]  Wenzhen Zhu,et al.  Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes , 2020, Investigative radiology.

[38]  Y. Nishimura,et al.  Focusing on Adenosine Receptors as a Potential Targeted Therapy in Human Diseases , 2020, Cells.

[39]  Ralph S. Baric,et al.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.

[40]  A. Mohammadbeigi,et al.  Effect of pentoxifylline on diabetic distal polyneuropathy in type 2 diabetic patients: A randomized trial , 2019, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[41]  B. Tai,et al.  A Small Group Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Daily Pentoxifylline in the Management of Patients With Erectile Dysfunction with Suboptimal Treatment Response to Sildenafil , 2019, Sexual medicine.

[42]  G. Koksal,et al.  Comparison of Antithrombin III and Pentoxifylline Treatments in Gram Negative Sepsis Patients Developing Disseminated Intravascular Coagulation , 2019, Medeniyet medical journal.

[43]  S. Carrier,et al.  Evaluation of Oral Pentoxifylline, Colchicine, and Penile Traction for the Management of Peyronie’s Disease , 2019, Sexual medicine.

[44]  Ali I. Al-Gareeb,et al.  Berberine and Pentoxifylline: A novel combination in amelioration of acute kidney injury. , 2019, JPMA. The Journal of the Pakistan Medical Association.

[45]  Weiming Zhao,et al.  Caffeine Inhibits NLRP3 Inflammasome Activation by Suppressing MAPK/NF-κB and A2aR Signaling in LPS-Induced THP-1 Macrophages , 2019, International journal of biological sciences.

[46]  Ali I. Al-Gareeb,et al.  Synergistic effect of berberine and pentoxifylline in attenuation of acute kidney injury , 2019, International journal of critical illness and injury science.

[47]  A. Kolokythas,et al.  Management of osteoradionecrosis of the jaws with pentoxifylline-tocopherol: a systematic review of the literature and meta-analysis. , 2019, International journal of oral and maxillofacial surgery.

[48]  A. Voronkov,et al.  EXPERIMENTAL STUDY OF ANTI-THROMBOTIC ACTIVITY OF PENTOXYFILLIN MICROPARTICLES: BASED ON POLY-DL-LACTIDE-CO-GLYCOLIDE IN COMPARISON WITH PENTOXYFILLIN , 2019, Pharmacy & Pharmacology.

[49]  S. Harris,et al.  PENTOXIFYLLINE IN ACUTE ISCHEMIC STROKE PATIENTS WITH BLOOD HYPERVISCOSITY , 2018, International Journal of Applied Pharmaceutics.

[50]  M. Kaur,et al.  Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies , 2018, Cardiovascular Diabetology.

[51]  Monica Boen,et al.  Successful treatment of two individual cases of generalized granuloma annulare with amoxicillin/clavulanic acid and a combination of doxycycline and pentoxifylline. , 2018, Dermatology online journal.

[52]  Wei Lan,et al.  Pentoxifylline versus Steroid Therapy for Idiopathic Sudden Sensorineural Hearing Loss with Diabetes. , 2018, The journal of international advanced otology.

[53]  A. Çetinkaya,et al.  Protective effect of pentoxifylline on oxidative renal cell injury associated with renal crystal formation in a hyperoxaluric rat model , 2018, Urolithiasis.

[54]  J. D. de Haan,et al.  Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications , 2018, Front. Physiol..

[55]  Xinmei Yuan,et al.  Pentoxifylline exerts anti-inflammatory effects on cerebral ischemia reperfusion‑induced injury in a rat model via the p38 mitogen-activated protein kinase signaling pathway. , 2017, Molecular medicine reports.

[56]  Chuan-Fa Chang,et al.  Suppression of interleukin-6 increases enterovirus A71 lethality in mice , 2017, Journal of Biomedical Science.

[57]  S. Chehrei,et al.  Pentoxifylline besides naltrexone recovers morphine‐induced inflammation in male reproductive system of rats by regulating Toll‐like receptor pathway , 2017, Andrologia.

[58]  A. Wolberg,et al.  Red blood cells in thrombosis. , 2017, Blood.

[59]  Ali I. Al-Gareeb,et al.  Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia , 2017, Asian Journal of Transfusion Science.

[60]  Jing Zhu,et al.  Inhibition of histone acetylation by curcumin reduces alcohol-induced fetal cardiac apoptosis , 2017, Journal of Biomedical Science.

[61]  A. Zanchetti,et al.  Effects of pentoxifylline on inflammatory markers and blood pressure: a systematic review and meta-analysis of randomized controlled trials , 2016, Journal of hypertension.

[62]  Yuguo Chen,et al.  Pentoxifylline Ameliorates Cardiac Fibrosis, Pathological Hypertrophy, and Cardiac Dysfunction in Angiotensin II-induced Hypertensive Rats , 2016, Journal of cardiovascular pharmacology.

[63]  K. Alzoubi,et al.  An evaluation of the effect of pentoxifylline on blood pressure and myocardial oxidative status following intake of western diet , 2015, Clinical and experimental hypertension.

[64]  G. Brito,et al.  Pentoxifylline reduces the inflammatory process in diabetic rats: relationship with decreases of pro-inflammatory cytokines and inducible nitric oxide synthase , 2015, Journal of Inflammation.

[65]  P. J. Simpson,et al.  Milk-derived bioactive peptides inhibit human endothelial-monocyte interactions via PPAR-γ dependent regulation of NF-κB , 2015, Journal of Inflammation.

[66]  M. Jafari-Sabet,et al.  Pentoxifylline Increases Antiadhesion Effect of Streptokinase on Postoperative Adhesion Formation: Involvement of Fibrinolytic Pathway , 2015, Indian Journal of Surgery.

[67]  H. El-Bassossy,et al.  Pentoxifylline alleviates hypertension in metabolic syndrome: effect on low-grade inflammation and angiotensin system , 2015, Journal of Endocrinological Investigation.

[68]  A. Gow,et al.  Pentoxifylline attenuates nitrogen mustard-induced acute lung injury, oxidative stress and inflammation. , 2014, Experimental and molecular pathology.

[69]  G. Brito,et al.  Pentoxifylline decreases glycemia levels and TNF-alpha, iNOS and COX-2 expressions in diabetic rat pancreas , 2014, SpringerPlus.

[70]  S. Reddy,et al.  Reactive oxygen species in inflammation and tissue injury. , 2014, Antioxidants & redox signaling.

[71]  Y. Erbil,et al.  Preventive Effect of Pentoxifylline on Acute Radiation Damage via Antioxidant and Anti-inflammatory Pathways , 2010, Digestive Diseases and Sciences.

[72]  J. Wetterslev,et al.  Pentoxifylline for alcoholic hepatitis. , 2009, The Cochrane database of systematic reviews.

[73]  L. Multigner,et al.  Pentoxifylline and antioxidants improve sperm quality in male patients with varicocele. , 2009, Fertility and sterility.

[74]  V. Ravi,et al.  Pentoxifylline inhibits replication of Japanese encephalitis virus: a comparative study with ribavirin , 2008, International Journal of Antimicrobial Agents.

[75]  J. Francis,et al.  Cytokine blockade attenuates sympathoexcitation in heart failure: Cross‐talk between nNOS, AT‐1R and cytokines in the hypothalamic paraventricular nucleus , 2008, European journal of heart failure.

[76]  J. Nicolau,et al.  Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease--a randomized placebo-controlled study. , 2008, Atherosclerosis.

[77]  R. Daniel,et al.  Pentoxifylline Suppresses Transduction by HIV-1-Based Vectors , 2007, Intervirology.

[78]  J. Navarro,et al.  Renal Pro-Inflammatory Cytokine Gene Expression in Diabetic Nephropathy: Effect of Angiotensin-Converting Enzyme Inhibition and Pentoxifylline Administration , 2007, American Journal of Nephrology.

[79]  R. Salomão,et al.  Effect of pentoxifylline on lung inflammation and gas exchange in a sepsis-induced acute lung injury model. , 2006, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[80]  R. Porcher,et al.  Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  J. Navarro,et al.  Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. , 2005, Journal of the American Society of Nephrology : JASN.

[82]  A. Schreyer,et al.  Early treatment with pentoxifylline reduces lung injury induced by acid aspiration in rats. , 2005, Chest.

[83]  M. Peters-Golden,et al.  Leukotrienes: Underappreciated Mediators of Innate Immune Responses1 , 2005, The Journal of Immunology.

[84]  Lidong Zhang,et al.  Pentoxifylline inhibits endotoxin-induced NF-kappa B activation and associated production of proinflammatory cytokines. , 2004, Annals of clinical and laboratory science.

[85]  S. Sarin,et al.  Beneficial Effects of Tumor Necrosis Factor-α Inhibition by Pentoxifylline on Clinical, Biochemical, and Metabolic Parameters of Patients with Nonalcoholic Steatohepatitis , 2004, American Journal of Gastroenterology.

[86]  F. Martinez-Morales,et al.  Pentoxifylline Diminishes the Oxidative Damage to Renal Tissue Induced by Streptozotocin in the Rat , 2004, Experimental diabesity research.

[87]  N. Dhalla,et al.  Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. , 2004, Experimental and clinical cardiology.

[88]  W. Loomis,et al.  Pentoxifylline reduces acute lung injury in chronic endotoxemia. , 2003, The Journal of surgical research.

[89]  H. Dai,et al.  Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. , 2003, Chest.

[90]  S. El-Shenawy,et al.  The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat. , 2003, Pharmacological research.

[91]  I. Bayram,et al.  Effects of erythropoietin and pentoxifylline on the oxidant and antioxidant systems in the experimental short bowel syndrome , 2003, Cell biochemistry and function.

[92]  T. Alexy,et al.  In Vitro Antioxidant Properties of Pentoxifylline, Piracetam, and Vinpocetine , 2002, Clinical neuropharmacology.

[93]  A. Nicolaides,et al.  Treatment of retinal vein thrombosis with pentoxifylline: a controlled, randomized trial. , 2002, Angiology.

[94]  M. Murtaugh,et al.  Effects of pentoxifylline on inflammatory cytokine expression and acute pleuropneumonia in swine. , 2002, Immunobiology.

[95]  Yang Yejin.  Effect of pentoxifylline on the expression level of TNF-α induced by respiratory syncytial virus-infected human alveolar macrophages , 2001 .

[96]  A. Grabowska,et al.  Differential effects of pentoxifylline, a non-specific phosphodiesterase inhibitor, on the production of IL-10, IL-12 p40 and p35 subunits by murine peritoneal macrophages. , 2000, Immunopharmacology.

[97]  U. Costabel,et al.  Pentoxifylline Inhibits TNF- α Production from Human Alveolar Macrophages , 1999 .

[98]  J. Redondo,et al.  Pentoxifylline inhibits adhesion and activation of human T lymphocytes. , 1998, Journal of immunology.

[99]  Rex N. Brogden,et al.  Pentoxifylline (Oxpentifylline) , 1995, Drugs & aging.

[100]  T. van der Poll,et al.  Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. , 1994, The Journal of clinical investigation.